Mesoblast Limited reported total revenues of $120.25 million for the fiscal year ended June 30, 2026, marking a 590% increase from $17.2 million in the prior year. RYONCIL (remestemcel-L) net product sales accounted for $115.15 million of the total, reflecting the company’s transition from a research-focused biotech to a commercial drug maker.
The company posted a net loss of $57.5 million, a 44% reduction from the $102.1 million loss in FY2025. Gross profit reached $110 million, while research and development expenses totaled $39.7 million, including $17.3 million for product development and $22.4 million for Phase 3 trials and regulatory activities. Selling, general and administrative expenses rose by $18 million. Cash and cash equivalents stood at $103 million as of June 30, 2026, with net operating cash usage of $43.8 million for the year.
A new $125 million credit facility replaced higher-cost debt, providing additional financial flexibility. The company’s shares closed 2.04% lower at $16.84 in regular trading, though after-hours activity recovered to $17.00. Analyst price targets average $35, according to consensus data.
RYONCIL’s commercial performance included $36 million in Q4 revenue, supported by 50+ U.S. transplant centers onboarded, 30+ formulary approvals, and 98% coverage of U.S. lives. The J-Code obtained in October 2025 enabled Medicaid reimbursement nationwide. Clinical data showed 84% survival outcomes in pediatric patients with steroid-refractory acute graft-versus-host disease after 28 days of treatment.
Mesoblast outlined expansion plans for RYONCIL in adult SR-aGvHD, targeting approximately 2,000 U.S. patients annually. A Phase 3 trial enrolling up to 40 sites is underway, with an interim analysis planned for Q4 2027. Early survival data indicated 76% survival at Day 100 for patients treated with RYONCIL after ruxolitinib or second-line failure, compared to a 25% survival rate at Day 100 with standard treatments.
The company’s rexlemestrocel-L program for chronic low back pain has enrolled 350 patients in Phase 3, exceeding the initial target of 300. A trial readout is expected in H2 2027, with a Biologics License Application submission anticipated in 2028. The addressable market exceeds $10 billion, with 85% of pain specialists reporting increased likelihood to recommend the therapy based on 12-month outcomes.
Mesoblast’s REVASCOR program for heart failure reported reduced major mucosal bleeding events in LVAD patients, from 15.6 to 3.8 per 100 subject-months at six months. Ischemic LVAD patients showed a drop in 12-month all-cause mortality from 30% to 9%. The company plans to file for FDA approval in LVAD patients to support label extensions for pre-LVAD chronic HFrEF.
The company holds a global patent portfolio of over 1,100 patents and patent applications, protected through 2044. CEO Silviu Itescu described the period as a successful transition, noting RYONCIL is a highly profitable standalone product with proceeds reinvested into Phase 3 programs and manufacturing capacity.
